TY - JOUR
T1 - Clinical significance of mitochondrial DNA content in acute promyelocytic leukaemia
AU - Pereira-Martins, Diego A.
AU - Coelho-Silva, Juan L.
AU - Weinhäuser, Isabel
AU - Franca-Neto, Pedro L.
AU - Silveira, Douglas R.
AU - Ortiz, César
AU - Moreira-Aguiar, Amanda
AU - Lima, Marinus M.
AU - Koury, Luisa C.
AU - de Melo, Raul A.
AU - Glória, Ana B.
AU - Fagundes, Evandro M
AU - Lino, Bruno K.
AU - Pagnano, Katia
AU - Bittencourt, Rosane
AU - Nunes, Elenaide
AU - Traina, Fabiola
AU - Figueiredo-Pontes, Lorena
AU - Keating, Armand
AU - Tallman, Martin S.
AU - Ribeiro, Raul C.
AU - Dilon, Richard
AU - Ganser, Arnold
AU - Sanz, Miguel A.
AU - Berliner, Nancy
AU - Valk, Peter
AU - Löwenberg, Bob
AU - Ottone, Tiziana
AU - Noguera, Nelida I.
AU - Voso, Maria T.
AU - Paoloni, Francesca
AU - Fazi, Paola
AU - Ammatuna, Emanuele
AU - Huls, Gerwin
AU - Schuringa, Jan Jacob
AU - Rego, Eduardo M.
AU - Lucena-Araujo, Antonio R.
N1 - Funding Information:
This investigation was supported by (CNPq; grant # 303479/2018‐3) and (FAPESP, Grant #2013/08135‐2). D.A.P.M. (Grant #2017/23117‐1), J.L.C.‐S. (Grant #2016/23191‐4) and I.W. (Grant #2015/09228‐0) received a fellowship from FAPESP. I.W and D.A.P‐M were sponsored by the Abel Tasman Talent Program of the Graduate School of Medical Sciences of the University of Groningen/University Medical Center Groningen, The Netherlands. Conselho Nacional de Desenvolvimento Científico e Tecnológico Fundação de Amparo à Pesquisa do Estado de São Paulo
Publisher Copyright:
© 2022 British Society for Haematology and John Wiley & Sons Ltd.
PY - 2023/1
Y1 - 2023/1
N2 - Although a growing body of evidence demonstrates that altered mtDNA content (mtDNAc) has clinical implications in several types of solid tumours, its prognostic relevance in acute promyelocytic leukaemia (APL) patients remains largely unknown. Here, we show that patients with higher-than-normal mtDNAc had better outcomes regardless of tumour burden. These results were more evident in patients with low-risk of relapse. The multivariate Cox proportional hazard model demonstrated that high mtDNAc was independently associated with a decreased cumulative incidence of relapse. Altogether, our data highlights the possible role of mitochondrial metabolism in APL patients treated with ATRA.
AB - Although a growing body of evidence demonstrates that altered mtDNA content (mtDNAc) has clinical implications in several types of solid tumours, its prognostic relevance in acute promyelocytic leukaemia (APL) patients remains largely unknown. Here, we show that patients with higher-than-normal mtDNAc had better outcomes regardless of tumour burden. These results were more evident in patients with low-risk of relapse. The multivariate Cox proportional hazard model demonstrated that high mtDNAc was independently associated with a decreased cumulative incidence of relapse. Altogether, our data highlights the possible role of mitochondrial metabolism in APL patients treated with ATRA.
KW - ATRA
KW - anthracycline-based chemotherapy
KW - mtDNA content
KW - oxidative phosphorylation
UR - http://www.scopus.com/inward/record.url?scp=85140053688&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140053688&partnerID=8YFLogxK
U2 - 10.1111/bjh.18510
DO - 10.1111/bjh.18510
M3 - Article
C2 - 36263593
AN - SCOPUS:85140053688
SN - 0007-1048
VL - 200
SP - 170
EP - 174
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 2
ER -